Brief: Paratek Pharmaceuticals Announces Fourth Quarter 2022 Results
16/03/2023 11:42
March 16 (Reuters) - Paratek Pharmaceuticals Inc
PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FULL-YEAR 2022 REVENUE
OF
$160.3 MILLION
* Q4 REVENUE $160.3 MILLION
* PARATEK PHARMACEUTICALS - CONTINUED PROGRESS ON RARE
DISEASE
NONTUBERCULOUS MYCOBACTERIA (NTM) & BARDA PROJECT BIOSHIELD
ANTHRAX PROGRAMS
* PARATEK PHARMACEUTICALS - NUZYRA GENERATED NET U.S. SALES
OF
$98.7 MILLION FROM CORE COMMERCIAL BUSINESS, A 45% INCREASE OVER
PRIOR YEAR
* QTRLY NET LOSS PER SHARE $0.13
* 2023 REVENUE EXPECTED TO BE IN RANGE OF $143.0 TO $158.0
MILLION
* CASH AND CASH EQUIVALENTS OF $34.2 MILLION AS OF DECEMBER
31,
2022
* Q4 EARNINGS PER SHARE VIEW $0.09, REVENUE VIEW $63.5
MILLION --
REFINITIV IBES DATA
* PARATEK PHARMACEUTICALS - EXPECTS TO BE ABLE TO FUND
OPERATIONS
BEYOND Q1 OF 2024 AND TO ACCELERATE ITS PATHWAY TO PROFITABILITY
Source text for Eikon: ID:nGNXsXnRQ
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million